Home Cart Sign in  
Chemical Structure| 143664-11-3 Chemical Structure| 143664-11-3

Structure of Elacridar
CAS No.: 143664-11-3

Chemical Structure| 143664-11-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Elacridar is an orally active inhibitor of P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP), used to examine the influence of efflux transporters on agent distribution to the brain and for cancer research.

Synonyms: GG918; GF120918; GW120918

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Elacridar

CAS No. :143664-11-3
Formula : C34H33N3O5
M.W : 563.64
SMILES Code : O=C(C(C=CC=C1C2=O)=C1NC3=C2C=CC=C3OC)NC4=CC=C(CCN5CC6=C(C=C(OC)C(OC)=C6)CC5)C=C4
Synonyms :
GG918; GF120918; GW120918
MDL No. :MFCD00912604
InChI Key :OSFCMRGOZNQUSW-UHFFFAOYSA-N
Pubchem ID :119373

Safety of Elacridar

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • P-gp

In Vitro:

Cell Line
Concentration Treated Time Description References
mouse splenic CD4+ effector T cells 0.1 μM 4 hours To study the effect of Elacridar on TNF expression, confirming Mdr1 function in T cells. PMC5741099
DPX2 cells 0.06, 0.17, 0.51, 1.54, 4.62, 13.89, 41.67 and 125 μM 48 hours To test the effect of Elacridar on PXR activation, results showed that Elacridar significantly inhibited PXR activation PMC4634205
Caki-1DC 5 μM 7 days Elacridar in combination with Sunitinib significantly reduced the survival rate of Caki-1DC cells compared to monotherapy. PMC7011538
Caki-1WT 5 μM 7 days Elacridar in combination with Sunitinib significantly reduced the survival rate of Caki-1WT cells compared to monotherapy. PMC7011538

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice FVB. Rag1−/− mice intraperitoneal injection 125 μg 5% Imiquimod cream Daily for up to 7 days To study the effect of Mdr1-deficient T cells in Rag1?/? mice, confirming the role of Mdr1 in intestinal immune homeostasis. PMC5741099
Mice huPXR/huCAR/huCYP3A4/3A7 mice Oral 10 mg/kg Once daily for 3 days To test the effect of Elacridar on Vemurafenib bioavailability, results showed that Elacridar significantly increased Vemurafenib bioavailability PMC4634205
nude mice Caki-1DC tumor model oral 30 mg/kg once daily for 5 days/week Elacridar in combination with Sunitinib significantly reduced the tumor volume of Caki-1DC compared to monotherapy. PMC7011538

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.77mL

0.35mL

0.18mL

8.87mL

1.77mL

0.89mL

17.74mL

3.55mL

1.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories